Biotricity (BTCY) Stock Price

Biotricity Price

NASDAQ·CLOSED
5.75
​
Market closed

Revenue has compounded at 80.4% per year over the past 6 years to 13.79 M USD. Biotricity's net margin stands at -86.6%, up from -486.7% several years earlier. Biotricity currently offers a dividend yield of about 2.73%. Analysts set a median price target of 4.08 USD, implying 29.0% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Biotricity stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotricity business model & stock analysis

Biotricity, Inc. medical technology company. The company is headquartered in Etobicoke, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-10-26. The firm delivers remote biometric monitoring solutions, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. The company offers bioflux, an Electrocardiogram (ECG) monitoring system that enables physicians to diagnose cardiovascular diseases or coronary heart diseases, acts as an ambulatory monitor that detects arrhythmias, performs remote mobile cardiac telemetry diagnostic monitoring, and transmits ECG data via a built-in cellular radio in real time. The firm also provides biolife, a health and lifestyle solution for individuals, which consists of a device that monitors heart-rhythm or ECG, as well as respiration, calories, temperature, physical activity, and other.

Frequently asked questions about Biotricity

Analysts currently set an average price target of 4.08 USD for the Biotricity stock (median: 4.08 USD), implying -29.0 % versus the latest price. The consensus is based on 7 analyst ratings.

6 analysts currently rate the Biotricity stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Biotricity to generate revenue of 16.12 M USD and earnings per share of -0.33 USD.

Converted at the current exchange rate, the Biotricity share trades at 5.13 EUR (5.75 USD).

The Biotricity share (BTCY) is listed on 1 stock exchanges, including: NASDAQ (BTCY).

The expected revenue of Biotricity is 16.12 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biotricity is -7.03 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biotricity is currently -17.62. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biotricity stock.

The price-to-sales ratio (P/S) of Biotricity is currently 7.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biotricity stock.

The Eulerpool Quality Score for Biotricity is 4/10.

The ISIN of Biotricity is US09074H2031. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biotricity is A2DWS9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biotricity is BTCY. The ticker symbol is used to trade Biotricity shares on the stock exchange.

Fair ValueTerminal
5.92 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue per Employee
766,127.78 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Oct 26, 2015
ISIN
US09074H2031
Cusip
09074H104
Sedol
BYQGBX9
Market capitalization
123.77 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-17.62
P/S
P/Se
7.68
EV/EBIT
—
P/B Ratio
728.05
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
246.07 %
Last updated Oct 20, 2026, 9:37 PM

Biotricity Peer Group

Biotricity Ticker

NASDAQ · BTCY

All fundamentals and in-depth analysis of Biotricity

Our stock analysis for Biotricity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotricity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.